When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
DRNA - Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday
Dicerna Pharmaceuticals Inc.
Shares of Dicerna Pharmaceuticals (NASDAQ: DRNA) , a clinical-stage biopharmaceutical company, are tanking after a phase 2 clinical trial readout with the company's lead candidate, nedosiran. Investors left wondering about the company's next move pushed the stock 27.4% lower as of 2:22 p.m. EDT on Friday.
Dicerna Pharmaceuticals is developing nedosiran as a treatment for primary hypoxia (PH) types 1 and 2. Patients with this rare disorder produce too much oxalate that forms lots of painful kidney stones.